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We investigated 1) the ability of purified glargine (GLA), metab-
olites 1 (M1) and 2 (M2), IGF-I, and NPH insulin to activate the
insulin receptor (IR)-A and IR-B and IGF-I receptor (IGF-IR) in
vitro; 2) plasma concentrations of GLA, M1, and M2 during long-
term insulin therapy in type 2 diabetic patients; and 3) IR-A and
IR-B activation in vitro induced by serum from patients treated
with GLA or NPH insulin. A total of 104 patients (age 56.3 6 0.8
years, BMI 31.4 6 0.5 kg/m2, and A1C 9.1 6 0.1% [mean 6 SE])
were randomized to GLA or NPH insulin therapy for 36 weeks.
Plasma concentrations of GLA, M1, and M2 were determined by
liquid chromatography–tandem mass spectrometry assay. IR-A,
IR-B, and IGF-IR autophosphorylation was induced by purified
hormones or serum by kinase receptor activation assays. In vitro,
M1 induced comparable IR-A, IR-B, and IGF-IR autophosphory-
lation (activation) as NPH insulin. After 36 weeks, M1 increased
from undetectable (,0.2 ng/mL) to 1.5 ng/mL (0.9–2.1), while
GLA and M2 remained undetectable. GLA dose correlated with
M1 (r = 0.84; P, 0.001). Serum from patients treated with GLA or
NPH insulin induced similar IR-A and IR-B activation. These data
suggest that M1 rather than GLA mediates GLA effects and that
compared with NPH insulin, GLA does not increase IGF-IR sig-
naling during long-term insulin therapy in type 2 diabetes.
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Besides its typical metabolic effects, insulin alsohas growth effects. In 2009, four observationalstudies were published, of which three sug-gested that use of insulin glargine (GLA) was
associated with an increased risk of cancer (1–4). Since it
was shown that GLA had an increased affinity for the IGF-I
receptor (IGF-IR) (5,6), mitogenic effects of GLA were
believed to occur through increased stimulation of the
IGF-IR. However, we recently observed that serum from
type 2 diabetic patients, who were treated for 36 weeks with
metformin and GLA, induced similar IGF-IR activation
compared with that of patients treated with metformin and
NPH insulin (7).
After subcutaneous injection, GLA is metabolized into
two metabolites, M1 and M2 (8–10). GLA undergoes se-
quential cleavage of the COOH terminus of the B-chain,
forming metabolites M1 and M2 that lack the di-arginine
(M1 after removal of the two arginines, M2 with additional
deamination of threonine at position B30). M1 and M2
have the same metabolic properties as human insulin and
do not differ from human insulin in affinity for the IGF-IR
(5). Our previous observation of a lack of increase in IGF-IR
activation by serum (7) could have been the result of GLA
not reaching in vivo concentrations needed to stimulate
the IGF-IR (11). However, it may also be the result of
metabolism of GLA to M1 or M2 before it enters the cir-
culation. Pharmacodynamic studies have shown that in
type 1 diabetes mellitus, after a subcutaneous injection,
GLA is rapidly and dose-independently metabolized almost
completely into M1 (10). Moreover, in type 2 diabetic
patients, after a subcutaneous injection of a therapeutic
dose, GLA was minimally detectable in blood, and M2 was
undetectable in blood, whereas M1 accounted for most
(90%) of the plasma insulin concentration up to 31 h (8).
Yet, whether GLA accumulates during long-term GLA
therapy is still unknown.
Mitogenic effects of insulin may also occur via increased
stimulation of the insulin receptor (IR) (12). IRs are usu-
ally expressed at high levels in cancer cells (13,14).
Moreover, cells can express two IR isoforms (IR-A and
IR-B), generated by alternative splicing of the IR gene (15).
The two IR isoforms have slightly different biological
properties (15). IR-B is the classical form of the IR, which
is primarily expressed in liver, muscle, and adipose tissues
and predominantly mediates metabolic effects (15–18).
IR-A is expressed ubiquitously but is predominantly ex-
pressed in central nervous system, hematopoietic cells,
and cancer tissues and has predominantly mitogenic
effects (15–18).
The aims of the current study were to measure 1) the
ability of purified GLA, M1, M2, IGF-I, and NPH insulin to
activate IR-A, IR-B, and IGF-IR in vitro; 2) plasma con-
centrations of GLA and M1 and M2 during long-term in-
sulin therapy in type 2 diabetic patients; and 3) IR-A and
IR-B activation in vitro induced by serum from patients
treated with GLA or NPH insulin.
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RESEARCH DESIGN AND METHODS
In vitro effects of GLA, M1, M2, NPH insulin, and IGF-I on IR-A, IR-B,
and IGF-IR autophosphorylation (activation). Equimolar concentrations
of GLA (Lantus; Sanofi, Frankfurt amMain, Germany), M1 (provided by Sanofi),
M2 (provided by Sanofi), NPH insulin (Insulatard; Novo Nordisk, Bagsvaerd,
Denmark), and IGF-I (Austral Biologicals, San Ramon, CA) were tested in
a range of 0.1–100 nmol/L. IR-A, IR-B, and IGF-IR activation was measured by
kinase receptor activation (KIRA) assays as detailed below.
Concentrations of metabolites in serum and effects of serum on IR-A
and IR-B activation in vitro. Serum samples from type 2 diabetic patients
treated with GLA were used to measure concentrations of GLA, M1, and M2 by
liquid chromatography–tandem mass spectrometry assay (LCMS) (see RE-
SEARCH DESIGN AND METHODS) (vide infra) at baseline and after 36 weeks of GLA
treatment. Serum-induced IR-A and IR-B activation was measured by KIRA
assays as detailed below (RESEARCH DESIGN AND METHODS section) before and
after 36 weeks of insulin treatment in the same type 2 diabetic patients and in
type 2 diabetic patients treated with NPH insulin for 36 weeks. Serum samples
tested were samples obtained from the previously reported LANMET study
(19) in which extra serum samples had been collected as part of the original
protocol (104 of 110 LANMET participants). The LANMET study was a multi-
centre, open, randomized, parallel-group study. Briefly, in the LANMET study,
the efficacy and safety of bedtime GLA and metformin was compared with
NPH insulin and metformin treatment in insulin-naive, poorly controlled type 2
diabetic patients (HbA1c $8.0%). The study consisted of a 4-week run-in phase
and a 36-week treatment phase. It was performed at six sites in Finland and
one in the U.K. The study was performed in accordance with the Declaration
of Helsinki and good clinical practice as described by Note for Guidance
CPMP/ICH/135/95. Approval by institutional ethics committees, including
permission to obtain extra serum samples at 0 and 36 weeks, was obtained for
each participating site. All patients provided written informed consent before
entry into the study.
IR-A, IR-B, and IGF-IR KIRA assays using pure hormone, metabolites,
or serum. The IR-A, IR-B, and IGF-IR KIRA assays have been previously de-
scribed (20,21). All three assays use human embryonic kidney cells stably
transfected with either cDNA of the human IR-A or human IR-B gene (HEK
IR-A or IR-B) or with cDNA of the human IGF-IR gene (HEK IGF-IR). The
principle of all three KIRA bioassays is based on quantification of tyrosine
residue phosphorylation of the IR or IGF-IR. For the in vitro experiments, after
48 h of culture, cells were stimulated for 10 (for IR KIRA assays) or 15 min (for
the IGF-IR KIRA assay) at 37°C. Cells were stimulated with equimolar con-
centrations of GLA, M1, M2, NPH insulin, or human recombinant IGF-I diluted
in 0.5% human serum albumin (Octalbine; Octopharma, Lachen, Switzerland).
For serum experiments, after 48 h of culture, cells were stimulated for
10 min (for IR KIRA assays) at 37°C. Cells were stimulated with in serum or
increasing amounts of human recombinant insulin (Actrapid; Novo Nordisk) in
a range of 0.06–1.0 nmol/L. In addition, two control serum samples were tested
on every plate to ensure optimal performance. Standards and serum samples
were diluted in Krebs-Ringer bicarbonate buffer adjusted to pH 7.4 by CO2 and
supplemented human serum albumin diluted to 0.5 and 0.1%, respectively.
Serum samples were diluted 1:10.
After stimulation, cells were lysed. Crude lysates were transferred to
a sandwich assay. In the IR KIRA assays, wells were coated with a monoclonal
antibody directed against the IR (Novozymes-Gropep, Adelaide, Australia) that
was used as capture antibody in a concentration of 2.5 mg/mL. In the IGF-IR
KIRA assay, wells were coated with a monoclonal capture antibody directed
against the IGF-IR in a concentration of 5.0 mg/mL. A biotinylated anti-
phosphotyrosine monoclonal antibody (BAM 1676; R&D Systems Europe Ltd,
Abingdon, U.K.) was used in a concentration of 0.2 mg/mL together with
streptavidin-labeled europium (DELFIA Eu-N1; PerkinElmer Life Sciences,
Groningen, the Netherlands) in a concentration of 50 pmol/L as detection
antibody. Contents were read in a time-resolved fluorometer (Victor2 multi-
label counter; PerkinElmer Life Sciences). Assays were performed in 48-well
plates (Corning, Corning, NY). All measurements were done in duplicate. The
inter- and intra-assay CVs were ,15%.
GLA, M1, and M2 metabolite assays. Plasma GLA, M1, and M2 concen-
trations were determined in citrate plasma samples taken after an overnight fast
after 36 weeks of insulin treatment as follows: GLA, M1, and M2 were extracted
in plasma samples by immunoaffinity columns and quantified by a specific
LCMS, without cross-reactivity to endogenous human or other insulins. The
limit of quantitation was 33 pmol/L (0.2 ng/mL) (10).
Statistical analysis. Baseline characteristics are shown as means (or geo-
metric means) 6 SE. The Kolmogorov-Smirnov test was used to test normality
of variables (data were considered to be normally distributed when P . 0.05).
For data that did not meet the criteria for normality, logarithmic trans-
formations were applied and are presented as geometric means with 95% CI
or/ if logarithmic transformation did not normalize data, as medians with
interquartile range. Spearman correlation coefficients were calculated to as-
sess the associations between variables. Differences in continuous variables
were calculated by an unpaired t test or Mann-Whitney test. Differences in
categorical variables were tested by using the x2 test. A P value #0.05 was
considered statistically significant. Data were analyzed using SPSS 17 for
Windows (SPSS Inc., Chicago, IL).
RESULTS
Effects of purified GLA, M1, M2, and NPH insulin on
IGF-IR, IR-A, and IR-B activation in vitro
IGF-IR activation. As depicted in Fig. 1A, at 10–100
nmol/L GLA was significantly more potent than NPH in-
sulin or M1 and M2 to activate the IGF-IR. IGF-I was the
most potent activator of IGF-IR (Fig. 1A). M1 and M2 and
NPH insulin activated the IGF-IR in a comparable manner
(Fig. 1A).
FIG. 1. Activation of the IGF-IR (A), IR-A (B), and IR-B (C) in vitro: comparing equimolar concentrations of NPH insulin, human IGF-I, insulin
GLA, and M1 and M2. Dose-response profiles ranged from 0.1 to 100 nmol/L. Points represent the mean value (+ SEM) of three independent
experiments. *P < 0.05 compared with NPH insulin.
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IR-A activation. At 10–100 nmol/L, GLA and M2 were
more potent than NPH insulin in activating the IR-A (P ,
0.001) (Fig. 1B). M1 activates IR-A similarly to NPH insulin
at concentrations up to 100 nmol/L (Fig. 1B) and was only
slightly more potent than NPH insulin at 100 nmol/L (P =
0.04) (Fig. 1B).
IR-B activation. At 10–100 nmol/L, GLA and M2 were
more potent than NPH insulin in activating the IR-B (P ,
0.001) (Fig. 1C). M1 was as potent as NPH insulin over the
entire range tested (Fig. 1C).
Table 1 shows the half-maximal effective concentration
(EC50) values of IGF-I, NPH insulin, GLA, M1, and M2 for
IGF-IR, IR-A, and IR-B, respectively. For the IGF-IR, the
EC50 of GLA was substantially lower than NPH insulin,
while EC50 values for M1 and M2 were higher compared
with NPH insulin. For IR-A and IR-B, the EC50 values were
similar for NPH insulin, GLA, M1, and M2.
Plasma concentrations of GLA and its metabolites
after 36 weeks of therapy. As reported previously (7,19),
baseline characteristics were comparable (Table 2). At 36
weeks, the mean doses of GLA and NPH insulin to achieve
HbA1c of 7.0 6 0.1 and 7.1 6 0.1% (P = 0.93) were 68 6 6
and 71 6 6 IU/day (P = 0.68). The insulin doses were also
comparable (GLA, 0.69 6 0.05 vs. NPH, 0.69 6 0.05 IU/kg;
P = 0.98).
At 36 weeks of GLA treatment, plasma M1 concen-
trations increased from undetectable (,0.2 ng/mL) to 1.5
ng/mL (0.9–2.1) (median [interquartile range]), whereas
GLA and M2 concentrations remained undetectable (,0.2
ng/mL) (Fig. 2). The dose of insulin GLA (IU/kg) correlated
with M1 (r = 0.84; P , 0.001) (Fig. 3).
IR-A and IR-B activation in vitro, induced by serum
from patients in the GLA- versus NPH insulin–treated
groups. At baseline, serum-induced IR-A and IR-B activa-
tion did not differ between the two treatment groups (IR-A:
GLA vs. NPH insulin, 76 [63–91] (median [interquartile
range]) vs. 72 pmol/L [52–83]; P = 0.09; IR-B: 134 [106–166]
vs. 123 pmol/L [102–159]; P = 0.33).
At 36 weeks of insulin therapy, serum-induced IR-A and
IR-B activation did not differ between the two treatment
groups (IR-A: GLA vs. NPH insulin, 72 [54–82] vs. 71 pmol/L
[57–92]; P = 0.96; IR-B: GLA vs. NPH insulin, 116 [93–148]
vs. 121 pmol/L [102–133]; P = 0.65).
At 36 weeks, the insulin dose (IU/kg) was positively
correlated with serum-induced IR-A (r = 0.28; P = 0.004)
but not to IR-B activation (r = 0.16; P = 0.12). In the NPH
insulin–treated group, the insulin dose (IU/kg) was posi-
tively correlated with serum-induced IR-A (r = 0.39; P =
0.008) but not to IR-B activation (r = 0.24; P = 0.11) (Fig.
4A). In subjects treated with GLA, the insulin dose did not
correlate to serum-induced IR-A (r = 0.17; P = 0.22) or IR-B
activation (r = 0.08; P = 0.55). However, M1 correlated
with serum-induced IR-A (r = 0.33; P = 0.01) but not IR-B
(r = 0.17; P = 0.20) activation (Fig. 4B).
TABLE 1
EC50 values of IGF-I, NPH insulin, insulin GLA, M1, and M2 for human IR-A, human IR-B, and human IGF-IR
Receptor types
EC50 (nmol/L)
IGF-I NPH insulin Insulin GLA M1 M2
IR-A 9.6 6 1.0 1.8 6 1.0 2.2 6 1.1 2.2 6 1.1 2.0 6 1.1
IR-B 23.0 6 1.1 1.4 6 1.1 2.0 6 1.1 1.8 6 1.2 2.0 6 1.1
IGF-IR 1.1 6 1.2 40.0 6 1.4 23.4 6 1.3 85.1 6 1.9 49.1 6 1.8
Data are mean 6 SE of minimally three independent experiments.
TABLE 2
Baseline characteristics of diabetic patients randomized to the






Patients (n) 57 47 —
Sex (M/F) 35/22 31/16 0.63
Age (years)a 56.0 6 1.2 56.7 6 1.2 0.71
Metformin dose (g/day) 2.16 6 0.05 2.23 6 0.06 0.38
Previous sulfonylurea (%) 81 89 0.28
Weight (kg) 92.3 6 2.4 95.5 6 2.6 0.36
BMI (kg/m2)a 31.0 6 0.7 31.9 6 0.8 0.35
HbA1c (%)
a 9.0 6 0.1 9.2 6 0.2 0.33HbA1c (mmol/mol)
a 75 6 1.1 77 6 2.2
FPG (mmol/L)a 12.3 6 0.3 11.9 6 0.4 0.43
C-peptide (nmol/L) 1.0 6 0.04 1.0 6 0.07 0.86
Serum TG (mmol/L)a 2.0 6 0.2 2.2 6 0.2 0.17
HDL cholesterol (mmol/L)a 1.2 6 0.04 1.1 6 0.03 0.25
LDL cholesterol (mmol/L)a 2.7 6 0.1 2.8 6 0.1 0.40
Data are mean 6 SE. FPG, fasting plasma glucose; TG, triglycerides.
aGeometric mean. bP values are shown for differences between the
GLA group and NPH insulin group in the current study.
FIG. 2. Plasma concentrations of insulin GLA and its metabolites
M1 and M2 at baseline and at 36 weeks of insulin GLA therapy deter-
mined by LCMS. Results are shown as median with interquartile ranges.
The broken line shows the detection limit for all three substances
(0.20 ng/mL).
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DISCUSSION
The most important finding of this study was that there
was no detectable GLA in the circulation of type 2 diabetic
patients treated with high doses of GLA for 36 weeks. Of
the metabolites of GLA, only M1 could be detected in the
circulation of patients treated with GLA. Circulating M1
concentrations correlated closely with the GLA dose and
with the ability of serum (from the same patients) to in-
duce IR-A activation. In contrast to purified GLA, purified
M1 did not activate IGF-IR in vitro, even at high con-
centrations and activated IR-A and IR-B similar to NPH
insulin.
Sommerfeld et al. (6) found that GLA had a higher af-
finity for the IGF-IR and was also more potent than human
insulin to stimulate thymidine incorporation in Saos-2
cells. In contrast, M1 and M2 were significantly less active
than human insulin in binding to and activating the IGF-IR
(6). Their mitogenicity in Saos-2 cells was equal to that of
human insulin (6). In another study, IGF-I and GLA more
efficiently stimulated phosphatidyl-inositol 3 phosphate (3)
production in breast cancer–derived MCF-7 cells as com-
pared with human insulin (22). In contrast, as compared
with insulin, M1 and M2 showed lower potency in stimu-
lating hybrid receptors (IR/IGF-IR), they induced less
phosphatidyl-inositol 3 phosphate (3) production, less Akt
and extracellular signal–related kinase 1/2 phosphoryla-
tion, and less DNA synthesis in MCF-7 cells. These ex-
perimental results are in keeping with our findings of
slightly greater IR-A, IR-B, and IGF-IR activation at high
(supraphysiologic) concentrations by GLA compared with
human insulin and with data showing that GLA metabolites
M1 and M2 do not share these properties of GLA (Fig. 1
and Table 1).
These findings may thus explain why the ability of serum
from type 2 diabetic patients to induce IR-A and IR-B ac-
tivation in the GLA-treated group was comparable to that
of patients treated with NPH insulin. Moreover, they may
also explain why we previously were not able to detect
FIG. 3. Correlation between insulin GLA dose per kilogram per day at
36 weeks of insulin therapy and concentrations of its metabolite M1.
FIG. 4. A: Correlation between NPH insulin dose per kilogram per day and serum-induced IR-A and IR-B activation at 36 weeks of insulin therapy.
NPH dose per kilogram per day was positively related to IR-A activation. B: Correlation between concentrations of metabolite M1 and serum-
induced IR-A and IR-B activation at 36 weeks of GLA therapy. M1 concentrations were positively correlated to IR-A activation.
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differences in serum-induced IGF-IR activation between
patients treated with GLA or NPH insulin (7).
In a recent study, circulating concentrations of GLA, M1,
and M2 were determined in type 1 diabetic subjects after
a single subcutaneous dose of 0.3, 0.6, or 1.2 IU/kg GLA,
respectively (10). The authors concluded that GLA was
rapidly and nearly completely processed into M1. In an-
other study, nine type 2 diabetic subjects were investigated
after 1 week of GLA treatment (8). GLA was detected at
low concentrations in five of the nine subjects and at only
a few time points. In contrast, M1 was detected in all
subjects and accounted for most of the plasma insulin and
metabolic action of the injected GLA, while M2 was un-
detectable. In contrast to our study, these studies did not
include measurements of the ability of pure hormones or
serum from the patients to activate the IR-A, IR-B, and
IGF-IR. Moreover, these studies did not address long-term
effects of high-dose GLA treatment on GLA and its
metabolites. Nevertheless, our findings are in line and
consistent with conclusions of these latter studies.
The data in the present and our previous study (7) do
not give support to the idea that treatment with GLA in
type 2 diabetes leads to a stronger stimulation of the IRs or
IGF-IR than NPH insulin. In spite of that, we did find
a positive relationship between insulin dose and serum-
induced IR-A activation for both treatment groups. This
suggests that, irrespective of insulin type, there may be an
enhanced IR-A signaling in subjects who are treated with
relatively high insulin doses. Whether these results have
any clinical consequences is still uncertain. In a recent
study, in which an animal model of type 2 diabetes was
studied, no differences could be demonstrated in the de-
gree of colonic epithelial proliferation between animals
treated with GLA or NPH insulin (23). However, insulin
treatment as such did result in a higher degree of colonic
epithelial proliferation, suggesting that potential insulin-
mediated mitogenic properties are irrespective of the type
of insulin (23).
Finally, a few limitations of our study need to be
addressed. The LANMET study was not primarily designed
and performed to study the effects of insulin therapy on
IR-A–, IR-B–, or IGF-IR–stimulating activities. Therefore,
the current study is inevitably a post hoc analysis. Sec-
ondly, as for all in vitro systems, the IR-A and IR-B KIRA
assays do not mimic the exact in vivo conditions. The
autophosphorylation of the tyrosine residues at the
b-subunits of the IGF-IR and IRs does not necessarily give
insights into whether activation of the IGF-IR or IR by an
insulin analog results in a normal (i.e., balanced metabolic
and mitogenic) activity at cellular level in vivo. Thus, it
would be important also to study downstream signaling
pathways of the IGF-IR and IRs. However, lack of detect-
able GLA in plasma after long-term insulin therapy pre-
cludes any direct role of GLA in mediating metabolic or
mitogenic effects during insulin therapy. Another limita-
tion of the current study is that metabolite measurements
were performed at 0 and 36 weeks, but not at other time
points.
In conclusion, M1 induced similar IGF-IR, IR-A, and IR-B
activation as human insulin. After long-term, high-dose
GLA therapy, only M1, but not GLA nor M2, could be
detected in the circulation of type 2 diabetic patients. The
concentration of plasma M1 correlated with insulin dose
and also with IR-A–stimulating activity. Serum from type 2
diabetic patients treated with GLA or NPH insulin induced
similar IR-A and IR-B activation. Taken together, these
data show that long-term high-dose GLA therapy does not
increase IGF-IR signaling.
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